Grace Dy

MD

Medical Oncology

Dr. Dy is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2022

Cancers Treated:

Lung Mediastinal Mesothelioma Thymus

Specializing In:

Lung cancer Mesothelioma Thymic malignancies

Special Interests:

Phase I clinical trials Novel targets for lung cancer therapy

About Grace Dy

About Grace Dy

Positions

Roswell Park Comprehensive Cancer Center

Chief, Thoracic Oncology
Professor of Oncology
Department of Medicine

Background

Education and Training:

MD - University of Santo Tomas, Manila, Philippines

Residency:

Mayo Clinic College of Medicine, Rochester, MN

Fellowship:

Mayo Clinic College of Medicine, Rochester, MN

Board Certification:

Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine

Clinical Trials

Clinical Trials

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Featured on Cancer Talk

Featured Articles

Three Lung Cancer Myths, Dispelled

Lung Cancer Clinical Trials: Judi’s Story

Does Cancer Risk Increase with Age?

Frequently Searched Questions | Lung Cancer

Fighting Cancer with My Immune System: A Patient's Story

Why “One Size Fits All” Therapies Won’t Work for All Lung Cancers

Showing all3 of 6 CollapseView all

Publications

Publications

Full Publications list on PubMed

Sotorasib for Lung Cancers with KRAS p.G12C Mutation. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R. N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. N Engl J Med. 2020 Sep 24;383(13):1207-1217. doi: 10.1056/NEJMoa1917239. Epub 2020 Sep 20.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy. Dy GK, Prasad D, Kumar P, Attwood K, Adjei AA. J Thorac Oncol. 2021 Mar;16(3):e19-e20. doi: 10.1016/j.jtho.2020.11.019.
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, Ito F.Nat Commun. 2021 Mar 3;12(1):1402. doi: 10.1038/s41467-021-21619-0.
Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. Shaurova T, Dy GK, Battaglia S, Hutson A, Zhang L, Zhang Y, Lovly CM, Seshadri M, Goodrich DW, Johnson CS, Hershberger PA. Cancers (Basel). 2020 Mar 13;12(3):675. doi: 10.3390/cancers12030675.
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer. Goldman JW, Barve M, Patel JD, Wozniak A, Dowlati A, Starodub A, Owonikoko TK, Edenfield W, Laurie SA, Da Costa D, Lally S, Koch M, Kosloski MP, Hoffman D, Dy GK. Clin Transl Sci. 2021 Mar;14(2):664-670. doi: 10.1111/cts.12928. Epub 2020 Dec 19.
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis. Schlei Z, Tan W, Faber MG, Chen H, Meagher A, Dy GK. Clin Lung Cancer. 2018 Nov;19(6):467-475. doi: 10.1016/j.cllc.2018.05.017. Epub 2018 Jun 5.
Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events. Anwar S, Tan W, Hong CC, Admane S, Dozier A, Siedlecki F, Whitworth A, DiRaddo AM, DePaolo D, Jacob SM, Ma WW, Miller A, Adjei AA, Dy GK. Cancers (Basel). 2017 Jun 26;9(7):73. doi: 10.3390/cancers9070073.
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. Zhang H, Shao H, Golubovskaya VM, Chen H, Cance W, Adjei AA, Dy GK. Br J Cancer. 2016 Jul 12;115(2):203-11. doi: 10.1038/bjc.2016.190. Epub 2016 Jun 23.